Novo Nordisk: Jefferies downgrades to 'underperform'
(CercleFinance.com) - Today an analyst at Jefferies downgrades his rating on the Novo Nordisk share to "underperform".
"US oral sema approval is imminent but we envisage pricing nearer oral SGLT-2s, a significant discount to injectable GLP-1s... We hike oral sema sales above cons 2022+E given an encouraging proprietary US physician survey but assume a below-average gross margin," the broker says.
Jefferies confirms its target price of 300 kronor for the share.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"US oral sema approval is imminent but we envisage pricing nearer oral SGLT-2s, a significant discount to injectable GLP-1s... We hike oral sema sales above cons 2022+E given an encouraging proprietary US physician survey but assume a below-average gross margin," the broker says.
Jefferies confirms its target price of 300 kronor for the share.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.